Difference in forecasted sales for select gene therapies 2018 vs. 2021
As of March 2021, the 2024 sales forecast for Zolgensma stood at more than two billion U.S. dollars, while back in December 2018 it was predicted to be significantly smaller, at 1.4 billion dollars. This statistic illustrates the difference in forecasted 2024 sales for select gene therapies, comparing projections in 2018 and in 2021.